/tag/clinical-trial-endpoints/ Clinical Trial Endpoints Wowchemy (https://wowchemy.com)en-usTue, 28 Apr 2026 00:00:00 +0000 /media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_2.png /tag/clinical-trial-endpoints/ /software/visualprogressplotter/ Tue, 28 Apr 2026 00:00:00 +0000 /software/visualprogressplotter/ <h2 id="overview">Overview</h2> <p>VisualprogressPlotter is a desktop tool for plotting patient vision testing progress over time. It is designed for quick, consistent visualisation of right-eye and left-eye values across clinical visits.</p> <p><img src="patientprogressimage.png" alt="VisualprogressPlotter patient progress example"></p> <h2 id="intended-use">Intended use</h2> <p>Designed for research, audit, and educational use when reviewing longitudinal ophthalmic functional measurements. It is not intended for clinical diagnosis or direct patient management.</p> <h2 id="inputs">Inputs</h2> <ul> <li>Visit timings in months</li> <li>Visit labels such as baseline, month, or year labels</li> <li>Right-eye and left-eye values</li> <li>Test type selection for common visual function measures</li> </ul> <h2 id="features">Features</h2> <ul> <li>Default trial-style visit schedule from baseline to year 5</li> <li>OD and OS plotting on the same progress view</li> <li>Support for microperimetry mean sensitivity, volumetric sensitivity, BCVA letters, and LLVA letters</li> <li>Editable timepoints and labels</li> <li>Export of plots as PNG or PDF at 300 DPI</li> </ul> <h2 id="download">Download</h2> <ul> <li><a href="https://github.com/amanasj/VisualprogressPlotter/releases/tag/v0.91" target="_blank" rel="noopener">GitHub releases</a></li> </ul> /project/external-project/ Wed, 01 Jan 2025 00:00:00 +0000 /project/external-project/ <p>Clinical trials in inherited retinal disease need outcome measures that are sensitive to meaningful change and interpretable across patients, visits, and modalities.</p> <p>This project area brings together endpoint ranking, longitudinal modelling, visual function testing, and retinal imaging summaries to help identify measures that are robust enough for treatment evaluation.</p>